Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant

Cao, Yimei; Lu, Zengjun; Li, Pinghua; Sun, Pu; Fu, Yuanfang; Bai, Xingwen; Bao, Huang; Chen, Yingli; Li, Dong; Liu, Zaixin

doi:10.1016/j.jviromet.2012.03.036

Cited by 17 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liquid-phase blocking ELISA (LPB-ELISA) was used in the evaluation of antibody titers against FMDV after vaccination of cattle by a commercial LPB-ELISA kit from Lanzhou Veterinary Research Institute (LVRI; Lanzhou, Gansu, China) and performed according to the manufacturer's instructions (39).…”

Section: Methodsmentioning

confidence: 99%

Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Wang

Cao

et al. 2019

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Cattle are susceptible to foot-and-mouth disease virus (FMDV), and neutralizing antibodies are critical for protection against FMDV infection in this species. However, more information is needed on the host specific antigenic structure recognized by the FMDV-specific monoclonal antibodies (mAbs) and on the functional properties of the mAb that are produced in the natural host, cattle. Herein, we characterized 55 plasmablast-derived mAbs from three FMDV-infected cattle and obtained 28 FMDV-neutralizing antibodies by the single B cell antibody technique. The neutralizing mAbs (27/28) mainly recognized conformational epitopes that differ from the well-characterized immunodominant antigenic site 1 of FMDV as defined by murine mAbs. Of these FMDV-neutralizing mAbs, 13 mAbs showed intra-type broadly neutralizing activity against the three topotypes of FMDV serotype O (ME-SA, SEA, and Cathay topotypes). Moreover, all these intra-type broadly neutralizing antibodies competed with sera from FMDV infected or vaccinated cattle, which indicates their binding to native dominant epitopes, as revealed by a blocking ELISA. We further analyzed the germline V(D)J gene usage of the 55 FMDV-specific mAbs and found cattle IgG antibodies containing ultralong HCDR3 were exclusively restricted to usage of the germline gene segment VH 1-7*02. In addition, the restricted germline gene segments of VH 1-7*02 and VL1-47*01 or 1-52*01 pairing were observed in all IgG antibodies with ultralong HCDR3. Furthermore, antibodies with longer HCDR3 were more inclined to display FMDV-neutralizing activity. This study presents a novel method for screening FMDV-specific cattle mAbs which then provide the most useful tools for studying FMDV antigenic structure and variation.

show abstract

Section: Methodsmentioning

confidence: 99%

Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Wang

Cao

et al. 2019

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using Toll-like receptor (TLR) ligands as adjuvants to stimulate antigen-presenting cells is a popular approach, and there is some evidence that poly I:C (Polyinosinic:polycytidylic acid), a mimic of a virus-derived TLR3 ligand, can significantly increase cellular and humoral immune responses and reduce inter-individual variation in protection in pigs when combined with a multi-epitope subunit FMDV vaccine , supporting their earlier data in mice (Cao et al, 2012). Poly ICLC (poly-l-lysine and carboxymethyl cellulose) is another synthetic doublestranded RNA ligand for TLR3, and its inclusion in the Ad5-vectored FMD vaccine developed at PIADC resulted in an 80-fold reduction in the vaccine dose required for protection, with protection even observed in the absence of detectable FMDV-specific antibodies at the point of challenge (Diaz-San Segundo et al, 2014).…”

Section: Vaccine Adjuvantsmentioning

confidence: 84%

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Robinson

Knight-Jones

Charleston

et al. 2016

Transbound Emerg Dis

View full text Add to dashboard Cite

SummaryThis study assessed research knowledge gaps in the field of FMDV (foot-andmouth disease virus) vaccines. The study took the form of a literature review combined with research updates collected in 2014 from 33 institutes from across the world. Findings were used to identify priority areas for future FMD vaccine research. Vaccines play a vital role in FMD control, used both to limit the spread of the virus during epidemics in FMD-free countries and as the mainstay of disease management in endemic regions, particularly where sanitary controls are difficult to apply. Improvements in the performance or cost-effectiveness of FMD vaccines will allow more widespread and efficient disease control. FMD vaccines have changed little in recent decades, typically produced by inactivation of whole virus, the quantity and stability of the intact viral capsids in the final preparation being key for immunogenicity. However, these are exciting times and several promising novel FMD vaccine candidates have recently been developed. This includes the first FMD vaccine licensed for manufacture and use in the USA; this adenovirus-vectored FMD vaccine causes in vivo expression of viral capsids in vaccinated animals. Another promising vaccine candidate comprises stabilized empty FMDV capsids produced in vitro in a baculovirus expression system. Recombinant technologies are also being developed to improve otherwise conventionally produced inactivated vaccines, for example, by creating a chimeric vaccine virus to increase capsid stability and by inserting sequences into the vaccine virus for desired antigen expression. Other important areas of ongoing research include enhanced adjuvants, vaccine quality control procedures and predicting vaccine protection from immune correlates, thus reducing dependency on animal challenge studies. Globally, the degree of independent vaccine evaluation is highly variable, and this is essential for vaccine quality. Previously neglected, the importance of evaluating vaccination programme effectiveness and impact is increasingly being recognized.

show abstract

“…Several kinds of vaccine adjuvants have been studied for their potency to promote immune responses to FMDV vaccines. These adjuvants include mineral oil (ISA-206 and ISA-201) [3], saponins (Quil-A) [4], Tolllike receptor (TLR) ligands (targeting pattern recognition receptors) [5,6], cytokines (IFN-a, IFN-g, IL-1, IL-2, IL-15, IL-18 and GM-CSF) [7][8][9] and liposomes [10]. Currently the commercial FMDV adjuvants used include mineral oil-based adjuvants such as Montanide ISA-206, ISA-201, and aluminum hydroxide.…”

Section: Introductionmentioning

confidence: 99%

Layered double hydroxide nanoparticles as an adjuvant for inactivated foot-and-mouth disease vaccine in pigs

Zhang

Yin

et al. 2020

BMC Vet Res

View full text Add to dashboard Cite

Background Foot-and-mouth disease (FMD) is a highly transmissible disease that leads to vast economic losses in many countries. Prevention using inactivated vaccines is one effective measure used to control FMD. Unfortunately, inactivated FMD vaccines provide only short-term protection and require a cold-chain system. In recent years, many studies have shown that layered double metal hydroxides (LDHs) carrying antigens can be used to strongly induce immune responses. In this study, LDH nanoparticles (NPs) were prepared by hydrothermal synthesis. LDH particle size, electric potential, and morphology were measured and observed. The adsorption capacity of LDH NPs to FMDV was tested. The effects of LDH as an adjuvant on inactivated FMDV vaccines were further evaluated and compared with commercial FMDV Montanide ISA-206 in BALB/C female mice and Yorkshire pigs. Results LDH NPs were successfully prepared with a uniform particle size of ~ 87.21 nm, regular edges, a loose hexagonal shape and positive zeta charge of 32 mV. The maximum absorption concentration was 0.16–0.31 μg FMDV/μg LDH. In the mouse experiment, antibody levels in group LDH + FMDV were significantly higher compared to group saline + FMDV (P < 0.01) from days 42–98 and were significantly higher to group ISA-206 + FMDV on day 56 post-immunization (P < 0.05). After day 14 post-immunization, IFN-γ content was significantly increased (P < 0.05). In the pig experiment, antibody levels in both the ISA-206 + FMDV and LDH + FMDV were positive and were significantly higher compared with the PBS group on day 7 (P < 0.005). Antibody levels in 90% pigs were positive on day 56 in the LDH group. The neutralizing antibody levels in the LDH and ISA-206 groups were significantly higher from days 7–28 compared to the PBS control group (P < 0.05). Thus, LDH NPs were effective at inducing an immune response against FMDV. Conclusions LDHs with a loose hexagonal shape and a positive charge were prepared and evaluated as adjuvant for FMD vaccine. It was demonstrated that LDHs can induce immune responses in mice and pigs. In addition, the LDHs produced antibodies continuously which may indicate a slow-release effect. The study shows that LDHs may act as a potentially useful FMDV adjuvant.

show abstract

Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and poly-cytidylic acid as an adjuvant

Cited by 17 publications

References 31 publications

Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Layered double hydroxide nanoparticles as an adjuvant for inactivated foot-and-mouth disease vaccine in pigs

Contact Info

Product

Resources

About